查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1636006

2025-2033年按世代類型、抗癲癇藥物類型、配銷通路和地區分類的癲癇藥物市場

Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2024年全球癲癇藥物IMARC Group規模達25億美元。全球癲癇盛行率不斷上升、藥物開發和創新的顯著進步、人們對癲癇及其治療方案的認知不斷提高、醫療保健支出不斷增加和治療機會的增加是推動市場成長的一些關鍵因素。

癲癇藥物是指用於治療癲癇的藥物，癲癇是一種中樞神經系統 (CNS) 疾病，會導致不可預見的、無端的、反覆發作的癲癇發作。癲癇會影響各種精神和身體功能，導致突然的行為改變、感覺、意識喪失和嚴重的情緒困擾。其藥物包括第一代、第二代和第三代抗癲癇藥物 (AED)，例如透過口服、靜脈注射 (IV) 和肌肉注射途徑給藥的片劑、膠囊、液體和糖漿。癲癇藥物廣泛用於治療各種癲癇發作，包括局部性癲癇發作、難治性癲癇發作、混合性癲癇發作、強直陣攣性癲癇發作和急性反覆癲癇發作。癲癇藥物是安全的，具有更好的耐受性，可以預防危及生命的不良反應，並最大限度地減少對認知功能的負面影響。

目前，由於神經系統疾病、產傷、感染、藥物濫用和道路傷害發病率的增加，癲癇盛行率不斷上升，這是推動市場成長的主要因素之一。癲癇藥物廣泛用於消除癲癇發作、減少癲癇發作頻率、避免長期治療的不良影響，從而幫助患者恢復正常的心理和職業活動，維持正常的生活方式。除此之外，容易罹患嚴重疾病（例如可能導致癲癇發作的腦癌）的老年人口數量不斷增加，也是另一個主要的生長誘導因素。此外，廣泛的研究和開發（R＆D）活動旨在開發新的和先進的藥物，這些藥物價格實惠，可提高耐受性和療效，同時減少副作用，目前正在對市場成長產生積極影響。除此之外，最近開發的緩釋（ER）藥物配方允許更長的給藥間隔，同時最大限度地減少血清藥物水平的波動，從而與立即釋放（IR）藥物相比提高療效和依從性，正在促進市場發展生長。此外，政府實施各種措施來教育大眾了解這種疾病、促進研究並透過加速提供更好的治療方案來提供積極支持，正在推動市場成長。其他因素，包括新藥批准量的增加、醫療基礎設施的快速改善、公眾對神經系統疾病可用治療方法的認知不斷提高，以及與癲癇相關的恥辱感的減少，預計將推動市場成長。

本報告回答的關鍵問題：

  • 迄今為止，全球癲癇藥物市場表現如何，未來幾年將如何表現？
  • 全球癲癇藥物市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球癲癇藥物市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的癲癇藥物市場？
  • 根據世代類型，市場的分類是怎麼樣的？
  • 癲癇藥物市場中哪一代最有吸引力？
  • 根據抗癲癇藥物類型，市場的細分如何？
  • 癲癇藥物市場上最具吸引力的抗癲癇藥物類型是什麼？
  • 基於配銷通路的市場區隔是什麼？
  • 癲癇藥物市場上最具吸引力的配銷通路是哪一個？
  • 市場競爭結構如何？
  • 全球癲癇藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球癲癇藥物市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按世代類型

  • 第一代藥物
    • 市場趨勢
    • 關鍵環節
      • 苯妥英
      • 卡馬西平
      • 奧卡西平
      • 丙戊酸鈉
      • 乙舒醯亞胺
      • 撲米酮
      • 苯巴比妥
    • 市場預測
  • 第二代藥物
    • 市場趨勢
    • 關鍵環節
      • 左乙拉西坦
      • 拉莫三嗪
      • 托吡酯
      • 普瑞巴林
      • 盧非醯胺
      • 唑尼沙胺
    • 市場預測
  • 第三代藥物
    • 市場趨勢
    • 關鍵環節
      • 拉科醯胺
      • 吡崙帕奈
      • 醋酸艾斯利卡西平
      • 埃佐加濱/瑞替加濱
    • 市場預測

第 7 章：市場細分：按抗癲癇藥物類型

  • 窄譜 AED
    • 市場趨勢
    • 市場預測
  • 廣譜 AED
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場趨勢
    • 市場預測
  • 藥局
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Alkem Laboratories Limited
    • Bausch Health Companies Inc.
    • Eisai Co. Ltd.
    • GSK plc
    • H. Lundbeck A/S
    • Jazz Pharmaceuticals plc
    • Novartis AG
    • Pfizer Inc.
    • Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.)
    • UCB SA
Product Code: SR112025A6650

The global epilepsy drugs market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.6 Billion by 2033, exhibiting a growth rate (CAGR) of 6.87% during 2025-2033. The increasing prevalence of epilepsy worldwide, significant advancements in drug development and innovation, growing awareness about epilepsy and its treatment options, and rising healthcare expenditure and improving access to treatment are some of the key factors propelling the market growth.

Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictive, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.

At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.

Key Market Segmentation:

Generation Type Insights

First Generation Drugs

Phenytoin

Carbamazepine

Oxcarbazepine

Valproate

Ethosuximide

Primidone

Phenobarbital

Second Generation Drugs

Levetiracetam

Lamotrigine

Topiramate

Pregabalin

Rufinamide

Zonisamide

Third Generation Drugs

Lacosamide

Perampanel

Eslicarbazepine Acetate

Ezogabine/Retigabine

The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.

Anti-Epileptics Drugs Type Insights

Narrow-Spectrum AEDs

Broad-Spectrum AEDs

Distribution Channel Insights

Hospital Pharmacy

Pharmacy Stores

Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for epilepsy drugs. Some of the factors driving the North America epilepsy drugs market growth include increasing burden of epilepsy, rising awareness campaigns, launching of new products, etc.
  • Competitive Landscape
  • The report has also provided a comprehensive analysis of the competitive landscape in the global epilepsy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global epilepsy drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global epilepsy drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global epilepsy drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive epilepsy drugs market?
  • What is the breakup of the market based on the generation type?
  • Which is the most attractive generation type in the epilepsy drugs market?
  • What is the breakup of the market based on the anti-epileptics drugs type?
  • Which is the most attractive anti-epileptics drugs type in the epilepsy drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the epilepsy drugs market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global epilepsy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Epilepsy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Generation Type

  • 6.1 First Generation Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Phenytoin
      • 6.1.2.2 Carbamazepine
      • 6.1.2.3 Oxcarbazepine
      • 6.1.2.4 Valproate
      • 6.1.2.5 Ethosuximide
      • 6.1.2.6 Primidone
      • 6.1.2.7 Phenobarbital
    • 6.1.3 Market Forecast
  • 6.2 Second Generation Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Levetiracetam
      • 6.2.2.2 Lamotrigine
      • 6.2.2.3 Topiramate
      • 6.2.2.4 Pregabalin
      • 6.2.2.5 Rufinamide
      • 6.2.2.6 Zonisamide
    • 6.2.3 Market Forecast
  • 6.3 Third Generation Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Lacosamide
      • 6.3.2.2 Perampanel
      • 6.3.2.3 Eslicarbazepine Acetate
      • 6.3.2.4 Ezogabine/Retigabine
    • 6.3.3 Market Forecast

7 Market Breakup by Anti-Epileptics Drugs Type

  • 7.1 Narrow-Spectrum AEDs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Broad-Spectrum AEDs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacy Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Alkem Laboratories Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch Health Companies Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 GSK plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 H. Lundbeck A/S
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Jazz Pharmaceuticals plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Novartis AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Pfizer Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 SWOT Analysis
    • 14.3.11 UCB S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

List of Figures

  • Figure 1: Global: Epilepsy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Epilepsy Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Epilepsy Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Epilepsy Drugs Market: Breakup by Generation Type (in %), 2024
  • Figure 5: Global: Epilepsy Drugs Market: Breakup by Anti-Epileptics Drugs Type (in %), 2024
  • Figure 6: Global: Epilepsy Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Epilepsy Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Epilepsy Drugs (First Generation Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Epilepsy Drugs (First Generation Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Epilepsy Drugs (Second Generation Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Epilepsy Drugs (Second Generation Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Epilepsy Drugs (Third Generation Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Epilepsy Drugs (Third Generation Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Epilepsy Drugs (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Epilepsy Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Epilepsy Drugs (Pharmacy Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Epilepsy Drugs (Pharmacy Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Epilepsy Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Epilepsy Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: North America: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: North America: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: United States: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: United States: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Canada: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Canada: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Asia-Pacific: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Asia-Pacific: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: China: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: China: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Japan: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Japan: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: India: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: India: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: South Korea: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: South Korea: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Australia: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Australia: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Indonesia: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Indonesia: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Others: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Europe: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Europe: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Germany: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Germany: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: France: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: France: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: United Kingdom: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: United Kingdom: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Italy: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Italy: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Spain: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Spain: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Russia: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Russia: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Others: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Latin America: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Latin America: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Brazil: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Brazil: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Mexico: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Mexico: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Others: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Middle East and Africa: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Middle East and Africa: Epilepsy Drugs Market: Breakup by Country (in %), 2024
  • Figure 72: Middle East and Africa: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Global: Epilepsy Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 74: Global: Epilepsy Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Epilepsy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Epilepsy Drugs Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Epilepsy Drugs Market Forecast: Breakup by Generation Type (in Million USD), 2025-2033
  • Table 3: Global: Epilepsy Drugs Market Forecast: Breakup by Anti-Epileptics Drugs Type (in Million USD), 2025-2033
  • Table 4: Global: Epilepsy Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Epilepsy Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Epilepsy Drugs Market: Competitive Structure
  • Table 7: Global: Epilepsy Drugs Market: Key Players